Skip to content
Screener

ProShares UltraPro Short NASDAQ Biotechnology ZBIO Q4 2025 Annual earnings

Reported March 16, 2026 · Before market open

EPS-$1.10Miss by $0.10
Revenue estimate$13.3M
EPS estimate-$1.00

Next report

Nov 12, 2026 (in 2 months)
Revenue estimate$1.0M
EPS estimate-$1.22

FAQ

When did ProShares UltraPro Short NASDAQ Biotechnology report Q4 2025 earnings?
ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) reported Q4 2025 earnings on March 16, 2026 before market open.
What were ProShares UltraPro Short NASDAQ Biotechnology's Q4 2025 revenue and EPS?
ProShares UltraPro Short NASDAQ Biotechnology reported eps of $-1.10 for Q4 2025.
Did ProShares UltraPro Short NASDAQ Biotechnology beat estimates in Q4 2025?
EPS missed the consensus estimate of $-1.00 by $0.10.
How did ProShares UltraPro Short NASDAQ Biotechnology's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 72.4% from $-3.99.
Where can I find ProShares UltraPro Short NASDAQ Biotechnology's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001104659-26-027961) and the 10-K periodic report (0001104659-26-027964) directly on SEC EDGAR. The filing index links above go to sec.gov.